Cite
APA Citation
Laribi, K., Tempescul, A., Ghnaya, H., Denizon, N., Besançon, A., Anghel, A., Farhi, J., Truong, C., Lemaire, P., Poulain, S., Bolle, D., Ianotto, J. C., & Baugier de Materre, A. (n.d.). the bendamustine plus rituximab regimen is active against primary nodal marginal zone B‐cell lymphoma. Hematological oncology, 35(4), 536–541. http://access.bl.uk/ark:/81055/vdc_100055223771.0x00003b